Research progress of proprotein convertase subtilisin/kexin type 9 in myocardial infarction and ische-mia reperfusion
10.3969/j.issn.1008-0074.2024.01.22
- VernacularTitle:前蛋白转化酶枯草杆菌蛋白酶/Kexin9型在心肌梗死及缺血再灌注中的研究进展
- Author:
Ying-Han SUN
1
;
Bing-Chen LIU
Author Information
1. 哈尔滨医科大学附属第四医院心内科,黑龙江 哈尔滨 150001
- Keywords:
Myocardial infarction;
Myocardial ischemia;
Myocardial Reperfusion;
Proprotein convertase subtilisin/kexin type9 inhibitors
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2024;33(1):100-103
- CountryChina
- Language:Chinese
-
Abstract:
At present,proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitor has been widely used in clinical field as a fast and effective drug to reduce low density lipoprotein cholesterol(LDL-C),in addition to regulating LDL-C to affect the process of atherosclerosis.Clinical data show that PCSK9 is upregulated in ischemic heart,and downregulation of PCSK9 expression can benefit infarct size,post-infarct inflammation and remodeling,and cardiac dysfunction after ische-mia/reperfusion.In subjects with increased cardiovascular risk,PCSK9 inhibition was associated with reduced incidence rates of myocardial infarction,stroke,and coronary revascularization,as well as improved endothelial function.This article reviews the role of PCSK9 in myocardial infarction and ischemia-reperfusion after myocardial infarction.
